盘前异动综述：Xencor、Surgery Partners、Agenus 因 ESMO 数据与并购报道盘前大涨，催化均已实时重定价

U. S. stock futures stabilized Monday morning following back-to-back weekly losses for major benchmarks, driven by elevated oil prices and persistent skepticism around AI capital expenditures. Here are some of Monday's biggest stock movers: Biggest stock gainers Xencor ( XNCR ) +23.94% - Shares traded higher as Phase 1 ESMO 2026 data showed Xencor’s ( XNCR) experimental kidney cancer drug XmAb819 achieved a 45. 5% confirmed response rate (5 of 11) at the highest tested dose in advanced clear cell renal cell carcinoma, with 82% of patients progression-free at six months. Based on these preliminary results, Xencor plans to discuss an accelerated approval pathway with the FDA in early 2027 and launch a global Phase 3 trial by the end of 2027, backed by cash reserves extending into 2029. Surgery Partners ( SGRY ) +20.86% - The stock saw significant buying interest following a report by the Financial Times that Bon Secours Mercy Health is in advanced talks to acquire a majority, controlling stake, in Surgery Partners ( SGRY) in a transaction valuing the outpatient surgical provider at approximately $6B, including $3. 5B in debt. The proposed take-private deal, framed around $20 per share, a 25% premium over recent trading levels, would see existing investor Bain Capital retain its roughly 40% stake while allowing Bon Secours to expand its surgical platform across 176 facilities. Agenus ( AGEN ) +6.95% - Shares pushed upward after Phase 2 ESMO trial data showed that 72% of advanced dMMR colon cancer patients achieved a complete response, with no detectable cancer at surgery, following a six-week regimen of Agenus’s (NASDAQ: AGEN) investigational botensilimab and balstilimab combination. Overall, 83% met the primary endpoint of major pathologic response. At 15 months, all 18 patients were alive and 16 remained free of recurrence, bolstering prospects for pre-surgical immunotherapy despite the trial's small sample size. More on related stocks: